Analyst Ratings For Acer Therapeutics Inc (NASDAQ:ACER)
Today, HC Wainwright set its price target on Acer Therapeutics Inc (NASDAQ:ACER) to $55.00 per share.
There are 3 Buy Ratings, 1 Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Acer Therapeutics Inc (NASDAQ:ACER) is Buy with a consensus target price of $57.00 per share, a potential 152.44% upside.
Some recent analyst ratings include
- 8/17/2018-Acer Therapeutics Inc (NASDAQ:ACER) gets upgraded to Strong-Buy by Raymond James with a price target of $46.00
- 8/14/2018-Acer Therapeutics Inc (NASDAQ:ACER) had its Outperform rating reiterated by William Blair
- 2/26/2018-Acer Therapeutics Inc (NASDAQ:ACER) has coverage initiated with a Buy ➝ Buy rating and $70.00 price target
- On 8/1/2018 Life Science Ventures Vii Tvm, Director, bought 275,000 with an average share price of $18.00 per share and the total transaction amounting to $4,950,000.00.
- On 12/14/2017 Steve Aselage, Director, bought 2,000 with an average share price of $12.00 per share and the total transaction amounting to $24,000.00.
- On 11/18/2016 Timothy C Barabe, Director, sold 14,914 with an average share price of $0.55 per share and the total transaction amounting to $8,202.70.
- On 9/17/2014 Timothy C Barabe, Director, bought 10,000 with an average share price of $1.15 per share and the total transaction amounting to $11,500.00.
- On 9/16/2014 Neil K Warma, CEO, bought 10,000 with an average share price of $1.11 per share and the total transaction amounting to $11,100.00.
- On 12/18/2013 Karthik Radhakrishnan, CFO, bought 8,000 with an average share price of $1.70 per share and the total transaction amounting to $13,600.00.
- On 12/18/2013 Scott B Seaman, Director, bought 30,000 with an average share price of $1.70 per share and the total transaction amounting to $51,000.00.
About Acer Therapeutics Inc (NASDAQ:ACER)
Acer Therapeutics Inc., a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Recent Trading Activity for Acer Therapeutics Inc (NASDAQ:ACER)
Shares of Acer Therapeutics Inc closed the previous trading session at 22.18 −0.77 3.36% with shares trading hands.